BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
NASA to bring astronauts home from space station early due to a medical issue - 24 Home Rec center Hardware Decisions for Little Spaces
- 3Grasping the Qualifications Among Separation and Dissolution
- 4Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show
- 52025 among world's three hottest years on record, WMO says
- Most loved Caf\u00e9 Chain: Where Do You Get Your Caffeine Fix
- A Manual for Nations with Extraordinary Food
- Which Espresso Do You Like Best? Vote
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- Green Inflections: A Manual for Inside Plants
- Pick Your Top Method for starting the Morning
- Scientists document a death from a meat allergy tied to certain ticks
- Instructions to Pick the Right Tires for Your Slam 1500.
- Why screening for the deadliest cancer in the U.S. misses most cases
